Escitalopram
Explore 2 research publications tagged with this keyword
Publications Tagged with "Escitalopram"
2 publications found
2019
1 publicationFormulation and Evaluation of Escitalopram Nanoparticles by Employing Cutina As Lipid
Nanoparticles are submicron nano sized particles having the size range of about 1-100nm range. Because of their sub-microscopic size, they have unique material characteristics, and manufactured nanoparticles may find practical applications in a variety of areas, including medicine, engineering, catalysis, and environmental remediation. Escitalopram (ETP), an SSRI (selective serotonin reuptake inhibitor), and s-enantiomer of citalopram is exclusively used as an antidepressant. The drug shows extensive hepatic metabolism, reduced drug efficacy and potential side effects, which reduces its therapeutic index. So, the present study is focused on increasing the solubility and thus the bioavailability. The nanoparticles were prepared by using hot homogenization method by using Cutina as lipid, soya lecithin as lipophilic surfactant and PEG as hydrophilic surfactant. The prepared solid lipid Nanoparticles were evaluated for Drug content, entrapment efficiency and dissolution studies and stability studies and found that the Drug content ( 90.7%), Entrapment efficiency ( 86.1 %) and Drug release of ( 82.4%), Particle size( 796nm) and Zeta potential ( -29.4mV)
2016
1 publicationIsocratic RP-HPLC Method Development, Validation and Stability Indicating Studies for Simultaneous Determination of Escitalopram and Clonazepam In the Combined Dosage Form
A new rapid, sensitive and precise stability indicating HPLC method was developed on kromasil RP-C18 column (250mm X 4.6mm, 5µm), for the simultaneous analysis of Escitalopram and Clonazepam. Chromatographic separation was achieved at 229nm by using a mobile phase composed of methanol, acetonitrile and phosphate buffer (70: 28: 2, v/v). Retention time of escitalopram and clonazepam were found to be 2.67min and 3.46min respectively. Method validation was done as per the ICH guidelines. Good linearity was established in the concentration range of 50-300µg/ml and 2.5-15µg/ml by escitalopram and clonazepam respectively. Resolution of escitalopram and clonazepam was found to be 5.25. Percentage RSD of precision was found to be less than 2. The percentage assay of escitalopram and clonazepam in commercial formulation was found to be 99.18 and 99.22 respectively. Stability of the molecule was measured by inducing different stress conditions like acidic, basic, peroxide, thermal, light and UV light.
